The ctDNA concentration for two recurrent AML-related mutations, affecting the NPM1 and IDH2 genes, was measured between 2 and 14 times (mean = 8.7, std = 3.7) during the first 18 days after initiation of induction chemotherapy. This evidence concerns the gene IDH2 and acute myeloid leukemia.